Knight Therapeutics Inc. GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 8,127.81% | -47.98% | -236.11% | 88.13% | 100.84% |
| Total Depreciation and Amortization | 26.90% | 18.35% | 4.64% | 6.88% | -2.61% |
| Total Amortization of Deferred Charges | 6.37% | 6.37% | 6.37% | 2.25% | 2.25% |
| Total Other Non-Cash Items | 3,181.36% | 340.50% | 1,439.11% | -83.65% | -97.53% |
| Change in Net Operating Assets | 147.78% | 146.44% | 111.19% | -1,026.22% | -1,307.94% |
| Cash from Operations | 280.39% | 1,081.65% | 84.76% | -34.26% | -52.96% |
| Capital Expenditure | -155.62% | -145.85% | 26.08% | 20.79% | 17.21% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -82.08% | -93.68% | -93.68% |
| Cash Acquisitions | 89.10% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -76.18% | -75.35% | 89.66% | 2,083.28% | 206.87% |
| Cash from Investing | 99.10% | -233.56% | -564.83% | -1,503.38% | -286.87% |
| Total Debt Issued | -99.24% | 2,227.65% | 3,126.89% | 3,713.86% | 2,736.02% |
| Total Debt Repaid | -23.27% | -377.64% | -334.14% | -178.97% | -167.99% |
| Issuance of Common Stock | -4.23% | -29.56% | -26.55% | -22.36% | 78.39% |
| Repurchase of Common Stock | -11.85% | 7.92% | 28.36% | 62.71% | 63.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.99% | -5.42% | 0.28% | 18.73% | 27.04% |
| Cash from Financing | -478.50% | 68.30% | 117.28% | 145.97% | 143.49% |
| Foreign Exchange rate Adjustments | 635.68% | -199.34% | -278.19% | -60.26% | -3,045.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.55% | -107.82% | -122.05% | 286.41% | -33.40% |